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Accepted 7 October 2010Highly active antiretroviral therapy (HAART)–induced lipoatrophy is characterized by
hypoleptinemia and insulin resistance. Evidence suggests that pioglitazone and
recombinant methionyl human leptin (metreleptin) administration has beneficial effects
in human immunodeficiency virus (HIV)–infected lipoatrophic patients. This proof-of-
concept study aimed at evaluatingwhether the combination ofmetreleptin and pioglitazone
has favorable effects, above and beyond pioglitazone alone, on bothmetabolic outcomes and
peripheral lipoatrophy in HIV-infected patients on HAART. Nine HIV-positive men with at
least 6 months of HAART exposure, clinical evidence of lipoatrophy, and low leptin
concentrations (≤4 ng/mL) were placed on pioglitazone treatment (30 mg/d per os) and were
randomized to receive either metreleptin (0.04 mg/kg subcutaneously once daily; n = 5) or
placebo (n = 4) for 3 months in a double-blinded fashion. Compared with placebo,
metreleptin reduced fasting serum insulin concentration, increased adiponectin
concentration, reduced the homeostasis model assessment index of insulin resistance,
and attenuated postprandial glycemia in response to a mixed meal (all P ≤ .02), but did not
affect trunk and peripheral fat mass. HIV control was not affected, and no major adverse
effects were observed. Metreleptin administration in HIV-positive, leptin-deficient patients
with lipoatrophy treated with pioglitazone improves postprandial glycemia and insulin
sensitivity. Results from this pilot study should be confirmed in larger clinical trials.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Highly active antiretroviral therapy (HAART) significantly
reduces disease-associated mortality and morbidity in
patients with human immunodeficiency virus (HIV) infection;
however, its use has been linked with multiple metabolic, registration no NCT001
ool, Beth Israel Deacones
.edu (F. Magkos).
er Inc. All rights reservedabnormalities including insulin resistance, dyslipidemia, and
body fat redistribution (lipodystrophy), thereby increasing the
risk of cardiovascular disease [1,2]. Lipoatrophy, characterized
by generalized fat depletion, is present in 15% to 35% of HIV
patients on HAART [3] and is associated with hyperinsuline-
mia, dyslipidemia, and hypoleptinemia [4].40244.
s Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
.
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activated receptor–γ agonistwith insulin-sensitizing properties,
tends to increase total body fat and limb fat mass in HIV-
infected patients; but its effects on insulin sensitivity are
inconsistent [5-7]. We [8] and others [9] have demonstrated
that administration of recombinant methionyl human leptin
(metreleptin) improves insulin resistance but also reduces total
body fat in lipoatrophicHIVpatients. The reduction in total body
fat was not likely accompanied by worsening of peripheral
lipoatrophy because it wasmainly attributed to reduced central
fat deposition [8,9]. In the present proof-of-concept study, we
hypothesized that the addition of metreleptin to pioglitazone
treatment would result in a therapeutic benefit above and
beyond that observed on pioglitazone alone.2. Methods
2.1. Subjects
Nine adult men (age, 50 [range, 43-57] years; body mass
index, 26 [range, 23-29] kg/m2) with HIV-1 infection and at
least 6 months of cumulative HAART exposure, serum leptin
concentrations less thanor equal to 4ng/mL (mean, 2.6ng/mL),
and clinical evidence of lipoatrophy (developed after the
initiation of HAART) were recruited sequentially from the
infectious disease and primary care clinics at the Beth Israel
DeaconessMedical Center (BIDMC) and the Boston community
via advertisement. Exclusion criteria were history of fasting
hyperinsulinemia, hyperglycemia, impaired glucose tolerance,
type 2 diabetesmellitus, and dyslipidemia before the initiation
of HAART; abnormal hepatic and renal functions; active
infection other than HIV; overt hypo- and hyperthyroidism;
hypogonadism; hypercortisolism; treatment with steroids or
growth hormone; as well as alcoholism and drug abuse. The
study was approved by the BIDMC Institutional Review Board,
and subjects provided written informed consent.
2.2. Experimental protocol and study outcomes
All subjects followed the American Heart Association Step 2
diet for a 4-week lead-in phase. Thereafter, pioglitazone
treatment was started (30 mg/d per os); and subjects were
randomized in a double-blind fashion to receive either
metreleptin (n = 5; 0.04 mg/kg per day, self-injected subcuta-
neously once daily between 7:00 PM and 11:00 PM) or placebo
(n = 4; same volume and timing as leptin) for 3 months;
metreleptin and placebo were supplied by Amylin Pharma-
ceuticals (San Diego, CA). Study outcomes were assessed
before and after treatment. On each occasion, subjects arrived
in the laboratory in the morning, following an overnight fast.
After collection of a baseline blood sample, a standard low-fat
mixed meal test (Boost; 240 kcal, 17% from protein, 68% from
carbohydrate, and 15% from fat) was administered to evaluate
postprandial glucose and insulin metabolism. Body fat mass
and fat distribution were determined by using dual-energy
x-ray absorptiometry (QDR-4500; Hologic, Bedford, MA). The
next morning, after measurement of resting blood pressure
and heart rate, 7 subjects (3 on placebo and 4 on metreleptin)
underwent a short (50 minutes), insulin-modified (0.03 U/kg),intravenous glucose (300 mg/kg) tolerance test [10]. Subjects
were instructed to maintain their HAART regimen, physical
activity, and dietary habits during the course of the study.
2.3. Sample analysis and calculations
Commercially available assays were used for measuring
serum concentrations of leptin, adiponectin (both from Linco
Research, St Charles, MO), and insulin (Diagnostic Products,
Los Angeles, CA). Serum glucose, interleukin-6, glycosylated
hemoglobin, total cholesterol, high-density lipoprotein and
low-density lipoprotein cholesterol, and total triglyceride
concentrations; liver function indices; complete blood cell
counts; and HIV markers (HIV viral load, CD4 and CD8
lymphocyte counts) were assayed by using standard methods
at the BIDMC clinical laboratory. Trunk fat mass was
estimated from the whole-body dual-energy x-ray absorptio-
metry scan [8]. Areas under the concentration-vs-time curves
for glucose and insulin in response to the mixed meal were
calculated by using the trapezoidal rule. The homeostasis
model assessment (HOMA) index was calculated to evaluate
insulin resistance [11].
2.4. Statistical analysis
Statistical analyses were performed with Predictive Analytics
Software version 18.0 (SPSS, Chicago, IL). Differences between
groups at baseline were assessed with the Mann-Whitney U
test. To evaluate the effect of metreleptin treatment compared
with placebo, changes from baseline were compared between
groups by using nonparametric multivariate analysis of vari-
ance on rank scores, adjusting for the number of outcome
variables. Both on-treatment (n = 6; 3 on placebo and 3 on
metreleptin) and intention-to-treat (n = 9; 1 on placebo and 2 on
metreleptin whose missing values were replaced by carrying
forward the last observation) analyses were performed.
Descriptive data are presented as means ± standard error or
meanswith95%confidence interval fromthe intention-to-treat
analysis. A 2-tailed P value < .05 was considered significant.3. Results
At baseline, there were no significant differences between
metreleptin- and placebo-treated subjects in body mass
index (P = .56), body weight (P = .29), age (P = .33), and all
clinical and metabolic parameters (P ≥ .11). All patients
maintained their HAART regimen, physical activity, and
dietary habits stable throughout the study (self-report).
Treatment with metreleptin increased serum leptin concen-
trations (3.7 ± 0.1 to 16.5 ± 6.7 ng/mL) compared with placebo
(1.9 ± 0.7 to 3.4 ± 1.2 ng/mL) (P = .02).
One subject treated with metreleptin and one treated with
placebo withdrew from the study because of mild injection
site reactions; another subject on metreleptin dropped out for
personal reasons unrelated to the study procedures. Overall,
no major adverse effects were observed.
Metreleptin significantly reduced fasting serum insulin con-
centration and the HOMA index, but did not affect intravenous
glucose disappearance, fasting serum glucose concentration, or
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metreleptin significantly reduced postprandial glycemia without
affecting the insulinemic response to the meal (Fig. 1).
Treatment with metreleptin did not affect body mass
index, body fat mass and distribution, resting blood pressure
and heart rate, fasting serum lipid profile, and fasting
interleukin-6 concentration, but increased serum adiponectin
concentration compared with placebo (Table 1).
Changes in hematology parameters (white and red blood
cells, hematocrit, hemoglobin, platelets, total lymphocytes) as
well as HIV markers (viral load, CD4 and CD8 lymphocyte
counts) did not differ significantly between metreleptin and
placebo (all P ≥ .33; data not shown). However, alkaline
phosphatase was significantly reduced by metreleptin; and a
similar though not significant change was observed for liver
transaminases (Table 1).4. Discussion
Previous studies have shown that leptin replacement in
humans with HIV-related lipoatrophy improves hyperinsuli-
nemia and insulin resistance, reduces total body and trunk fat,Table 1 – Study outcomes before and after 3 months of placebo
men treated with pioglitazone
Placebo (n = 4) Metrele
Before After Before
Body composition
Body mass index (kg/m2) 26 ± 1 26 ± 1 27 ± 1
Body fat (%) 17 ± 1 17 ± 1 20 ± 1
Total body fat (kg) 13.0 ± 0.5 13.1 ± 0.8 17.0 ± 1.
Peripheral fat (kg) 3.8 ± 0.2 3.8 ± 0.2 5.2 ± 0.
Trunk fat (kg) 8.1 ± 0.4 8.2 ± 0.6 10.6 ± 1.
Insulin sensitivity
Fasting glucose (mg/dL) 119 ± 24 122 ± 23 116 ± 19
Fasting insulin (mU/L) 3.9 ± 0.7 5.7 ± 2.6 8.5 ± 1.
Glycosylated hemoglobin (%) 5.9 ± 0.5 5.9 ± 0.5 5.9 ± 0.
HOMA insulin resistance 1.2 ± 0.4 1.8 ± 0.8 2.3 ± 0.
Glucose disappearance slope (%) −2.9 ± 0.9 −2.4 ± 0.7 −2.9 ± 0.
Cardiovascular system
Systolic blood pressure (mm Hg) 121 ± 7 124 ± 4 128 ± 11
Diastolic blood pressure (mm Hg) 75 ± 7 75 ± 5 82 ± 6
Heart rate (beats/min) 79 ± 7 70 ± 7 79 ± 6
Lipid profile
Total cholesterol (mg/dL) 188 ± 18 183 ± 17 176 ± 11
Triglyceride (mg/dL) 239 ± 102 184 ± 101 179 ± 68
HDL cholesterol (mg/dL) 38 ± 2 44 ± 5 36 ± 1
LDL cholesterol (mg/dL) 107 ± 18 108 ± 7 104 ± 11
Adipocytokines
Adiponectin (μg/mL) 1.6 ± 0.3 1.9 ± 0.5 2.5 ± 0.
Interleukin-6 (pg/mL) 3.1 ± 0.8 5.2 ± 2.4 2.2 ± 0.
Serum liver enzymes
Alanine transaminase (U/L) 33 ± 4 45 ± 17 32 ± 4
Aspartate transaminase (U/L) 35 ± 3 27 ± 3 27 ± 3
Alkaline phosphatase (U/L) 84 ± 8 83 ± 9 85 ± 14
Values before and after treatment are means ± standard error; difference
density lipoprotein; LDL, low-density lipoprotein.
a P value from on-treatment analysis.
b P value from intention-to-treat analysis.mildly improves lipid profile, and does not affect peripheral fat
[8,9], whereas pioglitazone increases total body and peripheral
fat with no consistent effects on insulin sensitivity and blood
lipid profile [5-7]. In this pilot study, we found thatmetreleptin
reduces fasting insulin concentration and insulin resistance
(ie, HOMA) and attenuates postprandial glycemia in HIV-
positive subjects treated with pioglitazone.
It was recently demonstrated that metreleptin administra-
tion increases insulin sensitivity in the liver (ie, suppression of
glucose production) but not skeletal muscle (ie, stimulation of
glucose uptake) [9]. This is in agreement with our finding of
reduced fasting insulin andHOMA index becauseHOMAmainly
reflects hepatic, not muscle, insulin resistance [12]. Further-
more, hepatic glucose production is almost completely sup-
pressed during the intravenous glucose tolerance test;
therefore, intravenous glucose disappearance primarily reflects
skeletal muscle insulin sensitivity [13], whereas, following
ingestion of a mixed meal, hepatic glucose production is only
marginally suppressed [14]. Collectively, these observations
together with our findings suggest that metreleptin improves
postprandial glycemiaand insulin sensitivity, possibly byacting
at the level of the liver. The increase in adiponectin concentra-
tion after metreleptin treatment may also contribute to thisor metreleptin administration in HIV-infected lipoatrophic
ptin (n = 5) Treatment effect P a P b
After Placebo Metreleptin
27 ± 1 0.0 (−0.2, 0.3) 0.1 (−0.3, 0.5) .85 1.00
20 ± 1 0.2 (−0.9, 1.2) −0.3 (−1.0, 0.4) .55 .46
5 16.7 ± 1.7 0.16 (−0.85, 1.18) −0.28 (−0.87, 0.31) .55 .46
6 5.1 ± 0.7 0.02 (−0.07, 0.11) −0.03 (−0.17, 0.10) .55 .81
3 10.4 ± 1.3 0.15 (−0.79, 1.09) −0.22 (−0.65, 0.22) .55 .46
110 ± 15 2.8 (−3.3, 8.8) −5.6 (−27.6, 16.4) .32 .49
9 6.1 ± 2.3 1.8 (−4.5, 8.1) −2.4 (−6.6, 1.9) .02 .08
2 5.7 ± 0.2 0.0 (−0.2, 0.3) −0.1 (−0.4, 0.1) .14 .17
6 1.6 ± 0.5 0.6 (−1.3, 2.4) −0.7 (−1.7, 0.3) .02 .08
6 −3.2 ± 0.6 −0.2 (−1.5, 1.1) 0.2 (−0.5, 0.8) .64 .56
127 ± 12 3 (−10, 15) −1 (−11, 8) .57 .49
81 ± 6 0.3 (−8, 9) −1 (−8, 6) 1.00 .73
78 ± 5 −9 (−45, 27) −1 (−6, 3) 1.00 .91
190 ± 13 −5 (−47, 38) 14 (−18, 46) .33 .65
175 ± 71 −56 (−211, 99) −4 (−18, 10) .33 .49
38 ± 3 6 (−7, 20) 1 (−5, 7) .33 .22
117 ± 8 0.3 (−45, 46) 13.6 (−16, 43) .33 .65
4 4.0 ± 0.9 0.3 (−1.2, 1.7) 1.6 (−0.2, 3.4) .02 .08
5 2.0 ± 0.6 2.1 (−5.2, 9.4) −0.3 (−0.6, 0.1) .57 .35
26 ± 2 12 (−50, 74) −5 (−13, 2) .85 .82
23 ± 2 −8 (−25, 9) −4 (−9, 1) .85 .65
78 ± 14 −0.8 (−7.5, 6.0) −6.4 (−14.7, 0.9) .01 .07
scores are means with 95% confidence intervals. HDL indicates high-
Fig. 1 – Glucose (top) and insulin (bottom) concentrations and areas under the curve in response to a mixed meal before (white
symbols) and after (black symbols) 3 months of placebo or metreleptin administration in HIV-infected lipoatrophic men
treated with pioglitazone. Compared with placebo, metreleptin significantly attenuated postprandial glycemia (P = .02 and P =
.01 for the on-treatment and intention-to-treat analyses, respectively), but did not affect postprandial insulinemia (P = .57 and
P = .82, respectively).
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directly correlate with the insulin-mediated suppression of
hepatic glucose production in HIV-infected patients [15]. The
reduction in serum alkaline phosphatase and perhaps in liver
transaminases indicates that metreleptin resulted in an overall
improvement in liver function, although values for all these
enzymes were within reference range in both groups, whether
before or after treatment.
Limited available studies indicate that pioglitazone favorably
affects peripheral lipoatrophy in HIV-infected patients by
increasing total body and limb fat mass [5-7], whereas metre-
leptin reduces central fat deposition [8,9]. We hypothesized that
treatment with metreleptin plus pioglitazone would preserve
these beneficial effects. Although metreleptin decreased total
body and trunk fat in all subjects on treatment, the effect was
small (∼0.3 kg) and did not approach significance; andwe found
no indication of an improvement inperipheral lipoatrophy. This
could possibly be due to the short duration of our study, the low
metreleptin dose, and/or the small number of subjects. Earlier
reports provide evidence suggesting that the effects of metre-
leptin may be both time [8] and dose [9] dependent. It is also
likely that the duration of our experiment (3 months) was too
short for pioglitazone-induced changes in body composition to
manifest; previous studies reporting beneficial effects adminis-
tered the drug for longer periods of time (6-12 months) [5-7]. Infact, in one of these studies where interimmeasurements were
obtained at 3months, only trends but no statistically significant
effects of pioglitazone on body fat distributionwere observed [6].
Longer-term administration (≥6months)may thus be necessary
to detect the putative beneficial effects of pioglitazone. It is also
possible that the opposite effects of metreleptin [8,9] and
pioglitazone [5-7] on body fat cancel out when both drugs are
administered. Therefore, the combination of metreleptin with
pioglitazone may retain the insulin-sensitizing and hypoglyce-
mic effects of metreleptin while at the same time prevent the
decrease in fatmass induced bymetreleptin alone, andneeds to
be further studied by larger trials.
In conclusion, results from this pilot study indicate that
leptin replacement attenuates fasting insulinemia and insulin
resistance and improves postprandial glycemia in lipoatrophic
HIV-positivemen treatedwithpioglitazone. These preliminary
findingshave important clinical implications for the treatment
of HIV-related lipoatrophy andmetabolic syndrome, and need
to be replicated in larger and longer-term studies.Acknowledgment
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